Global Pharmaceuticals Outlook, 2022

Global Pharmaceuticals Outlook, 2022 Updated Research Available

The Digitalization of the Pharmaceuticals Value Chain is Opening up New Growth Opportunities for Stakeholders

INDUSTRY
Healthcare

SECTOR
Life Sciences

RELEASE DATE
08-Mar-2022

REGION
North America

DELIVERABLE TYPE
Market Outlook

RESEARCH CODE
PCC8-01-00-00-00

SKU
HC03516-GL-MO_26357

$4,950.00

Special Price $3,712.50 save 25 %

In stock

SKU

HC03516-GL-MO_26357

Skip to the end of the images gallery

Skip to the beginning of the images gallery

Global Pharmaceuticals Outlook, 2022
Published on: 08-Mar-2022 | SKU: HC03516-GL-MO_26357

Need more details?

$4,950.00

$3,712.50 save 25 %

DownloadLink

downloadable link $0.00

Link1 sample $0.00

Select all

Qty

Request Sample

Need more details?

Description

Frost & Sullivan offers an outlook for the global pharmaceuticals market for 2022-2026, including emerging trends and growth opportunities. Prioritizing booster doses over initial dose coverage is negatively impacting the global mitigation of the COVID-19 pandemic, which is resulting in severe implications on health and social and economic well-being and delaying endemicity. The ongoing pandemic has accelerated pharma and biotech companies' transformation, and clinical trial decentralization, data-driven R&D, the digitalization of the supply chain, and outsourcing have taken center stage.

The industry will focus on supply chain resilience and the adoption of innovative technologies to improve efficiency while ensuring that healthcare remains precise, preventive, and outcome-based in the promotion of social and financial inclusion. In 2021, the emphasis was on COVID-19 in terms of drug research and therapy administration; this trend is expected to change by the end of 2022, and oncology and CNS are expected to become leading growth areas for the pharma industry. Value-based care will take center stage and lead to a shift to platform- and data-based drug discovery and development models.

Key Issues Addressed

What is the size of the global pharmaceuticals industry from 2022 to 2026?
What are the dynamics around COVID-19 vaccination deployment and the path to endemicity?
How are advancements such as decentralization, blockchain, and new modalities driving the transformation of the pharmaceuticals value chain?
What is the current and future therapeutic, R&D, and investment outlook and how is it evolving?
Which growth opportunities can ecosystem participants leverage in the near future?

Author: Surbhi Gupta

Infographic

Table of Contents

Growth Environment

Key Highlights

Regional Impact of the COVID-19 Pandemic

Top Pharmaceuticals Industry Predictions for 2022

Strategic Imperatives

Why Is It Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top Three Strategic Imperatives on the Pharmaceuticals Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Market Trends

Market Segmentation and Scope

Key Trend 1—Strategies to Fight Long COVID-19

Key Trend 2—Data-driven R&D Approach

Key Trend 3—Intense Conflict between Affordability and Access

Key Trend 4—Biologics Driving Manufacturing Capacity and Capability Expansion

Global Pharmaceuticals Industry—R&D Expenditure Outlook

Key Therapeutic Areas Outlook

Biopharmaceuticals’ VC Investments and M&A Outlook

Macroeconomic Factors

Global GDP Growth

2022 Scenario Analysis—Quarterly Global Growth

Supply Chain Disruptions—Impact Analysis

Sustainability Initiatives—Impact Analysis

Revenue Trends, 2021

Global Pharmaceuticals Industry—Historic Sales and Forecast

Segment Performance—Historic Sales and Forecast

Revenue Forecast by Region

Key Predictions for 2022

Prediction 1

Prediction 2

Prediction 3

Prediction 4

Prediction 5

Small-molecules Segment Outlook, 2022

Small-molecules Market Snapshot, 2022

Small-molecules Market—Companies to Watch

Biologics Segment Outlook, 2022

Biologics Market Snapshot, 2022

Biologics Market—Companies to Watch

Growth Opportunity Universe

Growth Opportunity 1—Innovative Formulation and Delivery Technologies for RNA Therapeutics, 2022

Growth Opportunity 1—Innovative Formulation and Delivery Technologies for RNA Therapeutics, 2022 (continued)

Growth Opportunity 2—Contract Research, Development, and Manufacturing Services to Support Emerging Biopharmaceuticals Companies in Asia-Pacific, 2022

Growth Opportunity 2—Contract Research, Development, and Manufacturing Services to Support Emerging Biopharmaceuticals Companies in Asia-Pacific, 2022 (continued)

Growth Opportunity 3—Digital Therapeutics to Support Evidence-based Treatment and Medication Adherence in the EU, 2022

Growth Opportunity 3—Digital Therapeutics to Support Evidence-based Treatment and Medication Adherence in the EU, 2022 (continued)

Conclusions

Key Concluding Thoughts

Appendix

Market Definition—Pharmaceuticals and Biotechnology

Next Steps

Your Next Steps

Why Frost, Why Now?

List of Exhibits

Legal Disclaimer

List of Figures & Charts

List of Figures

Pharmaceuticals Industry: Implication for Key Stakeholders, Global, 2021–2026
Pharmaceuticals Industry: R&D Expenditure Forecast, Global, 2019–2026
Pharmaceuticals Industry: Therapeutic Segment Split, Global, 2022
Pharmaceuticals Industry: Therapeutic Segment Split, Global, 2026
GDP Growth of Advanced and Developing Economies, Global, 2015–2022
GDP Growth Scenario Analysis, Global, Q1 2019–Q4 2022
Pharmaceuticals Industry: Implications for Key Stakeholders, Global, 2021–2026
Pharmaceuticals Industry: Implications for Key Stakeholders, Global, 2021–2026
Pharmaceuticals Industry: Revenue Forecast by Segment, Global, 2021 and 2022
Biologics Market: Revenue Forecast, Global, 2019–2026
Pharmaceuticals Industry: Revenue Forecast by Scenario, Global, 2019–2026
Small Molecules Market: Revenue Forecast, Global, 2019–2026
Pharmaceuticals Industry: Revenue Forecast by Region, Global, 2022

Request Sample

Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Life Sciences research

13 Jan 2025 | Global | Market Outlook

Top 6 Growth Opportunities for the Digital Health Industry, 2025

Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...

Cybersecurity in Healthcare, United States, 2024

Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...

Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025

Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...

Frost Radar™: Enterprise Conversational AI in Healthcare, 2024

This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-car...

Generative AI in Payer and Provider IT Transformation, Global, 2024-2029

The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...

Report download
Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:

Strategic Imperatives
Growth Opportunities
Best Practices
Companies to Action

Impacting your company's future growth potential.

Details

Frost & Sullivan offers an outlook for the global pharmaceuticals market for 2022-2026, including emerging trends and growth opportunities. Prioritizing booster doses over initial dose coverage is negatively impacting the global mitigation of the COVID-19 pandemic, which is resulting in severe implications on health and social and economic well-being and delaying endemicity. The ongoing pandemic has accelerated pharma and biotech companies' transformation, and clinical trial decentralization, data-driven R&D, the digitalization of the supply chain, and outsourcing have taken center stage. The industry will focus on supply chain resilience and the adoption of innovative technologies to improve efficiency while ensuring that healthcare remains precise, preventive, and outcome-based in the promotion of social and financial inclusion. In 2021, the emphasis was on COVID-19 in terms of drug research and therapy administration; this trend is expected to change by the end of 2022, and oncology and CNS are expected to become leading growth areas for the pharma industry. Value-based care will take center stage and lead to a shift to platform- and data-based drug discovery and development models.--BEGIN PROMO--